Form 4 for CYTK CYTOKINETICS INC
Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-05 · accession 0001127602-24-008501 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-05 | 2024-03-05 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $6.67 | +28.6K | 167.6K | +21% | +$190.8K |
| DM | 2024-03-05 | 2024-03-05 | CYTK | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $67.56 | -32.6K | 139.0K | -19% | -$2.20M |
| D | 2024-03-05 | 2024-03-05 | CYTK | Malik Fady Ibraham | EVP Research, Development | M - OptEx | $0.00 | -28.6K | 28.6K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-05 | M | A | 28,604 | $6.67 | 167,577 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-05 | S | D | 4,000 | $67.53 | 138,973 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-05 | S | D | 28,604 | $67.56 | 138,973 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2024-03-05 | M | D | 28,604 | $0.00 | 28,605 | D | $6.67 · 2016-03-23 to 2026-02-23 | 28,604 Common Stock |